



Imaging biomarkers are key to detecting and treating cancer

Press Release

MEDIAN Technologies Announces Two New Project Awards* for a total amount of €410,000

*MEDIAN Technologies has been selected to manage medical images
in two new phase II clinical studies for liver cancer*

Sophia Antipolis, France – November 27, 2013 – MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has been selected to provide imaging solutions and services in two phase II clinical trials for Hepatocellular Carcinoma (HCC). These two trials are sponsored by a global biopharmaceutical company.

As part of the projects, imaging data would be acquired in 55 clinical sites based in 5 Asian and 5 European countries. Anticipated total enrollment would be 210 patients with forecasted clinical trial starts in early 2015.

For the first study, MEDIAN will provide imaging services, enabling imaging data collection and quality control. For the second study, MEDIAN will also provide image independent review services performed by radiologists using the MEDIAN LMS platform. MEDIAN LMS is a unique solution for the review of images and quantitative assessment of response to therapy in clinical trials.

The anticipated amount for the two projects, awarded through MEDIAN alliance with its strategic CRO partner, is € 410,000 (eq. \$ 554,000).

“We are proud of these new successes in Europe and Asia as it demonstrates the trust our biopharmaceutical clients have in our worldwide operational capabilities” said Nicolas Dano, Director of Business Development Europe and Asia.

Since the beginning of 2013, MEDIAN Technologies has recorded €4.3M (eq. \$5.8 M) of orders, including €1,0M of firm orders and €3.3M of project awards*.

[] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.*



Imaging biomarkers are key to detecting and treating cancer

ALMDT
LISTED
NYSE
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies provides advanced imaging solutions for diagnosing and monitoring cancer patients in clinical trials and in routine clinical practice. MEDIAN collaborates with institutes at the cutting edge of medical imaging, including the French National Institute for Computer Science and Control (INRIA), the University of Chicago, and the Swiss Federal Institute of Technology in Lausanne, Switzerland (EPFL). MEDIAN is present in the market through direct and indirect sales of its LMS solutions and through alliances with specialist cancer centers in Europe and the USA. MEDIAN has a strategic partnership with Canon for the development of new technologies, and a strategic partnership with the world's largest CRO to offer integrated imaging services for clinical trials to customers worldwide.

Based in Sophia Antipolis, France, MEDIAN was founded in 2002 by Fredrik Brag (CEO), Gérard Milhiet, and Arnaud Butzbach. The company has a staff of 45, over half of whom work in R&D, and has a US-based subsidiary in the Boston area.

MEDIAN has received the label "Innovative company" by OSEO and is listed on NYSE Euronext Paris' Alternext market (ISIN: FR0011049824, ticker: ALMDT).

For more information on MEDIAN, please visit: www.medianttechnologies.com

CONTACTS

MEDIAN Technologies

Fredrik Brag, CEO
+33 492 906 582
fredrik.brag@mediantechnologies.com

Press

ALIZE RP
Caroline Carmagnol
+ 33 664 189 959
caroline@alizerp.com

Christian Berg
+ 33 170 225 386
christian@alizerp.com

Investors

ACTIFIN
Anaïs de Scitivaux
+ 33 156 881 114
adescitivaux@actifin.fr